Étiquette : pharmacologie

Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c‑Fos and NeuN expression in the hypothalamus of rats Eric Murillo‑Rodríguez, Roger G. Pertwee, Raphael Mechoulam et al., 2021

Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c‑Fos and NeuN expression in the hypothalamus of rats Eric Murillo‑Rodríguez, Diana Millán‑Aldaco, Gloria Arankowsky‑Sandoval, Tetsuya Yamamoto, Roger G. Pertwee, Linda Parker and Raphael Mechoulam     Abstract Background : Cannabidiol (CBD), the non-psychotropic compound from Cannabis sativa, shows positive results on controlling several health disturbances; however, comparable data regarding additional chemical from C. sativa, such as cannabidiolic acid (CBDA), is scarce due to its instability. To address this limitation, a stable CBDA analogue, CBDA methyl ester (HU-580), was synthetized and showed CBDA-like effects. Recently, we described that HU-580 increased [...]

Lire la suite

Psychedelic psychiatry’s brave new world, Nutt, D., Erritzoe, D., & Carhart-Harris, R., 2020

Psychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020   After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.   Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]

Lire la suite

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins, Samuel D. Banister and Mark Connor, 2018

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins Samuel D. Banister and Mark Connor Handbook of Experimental Pharmacology, # Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/164_2018_143   Contents 1 Introduction 2 Chemical Classification of Synthetic Cannabinoid Receptor Agonists 3 Cannabinoid Type 1 Receptor (CB1) Structure and Function 4 Historical Synthetic Cannabinoid Receptor Agonists 4.1 Classical Cannabinoids and Phytocannabinoid Analogs 4.2 Nonclassical Cannabinoids 4.3 Aminoalkylindoles (AAIs) 5 Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances 5.1 Molecular Hybridization 5.2 Bioisosteric Fluorination 6 Conclusions References Abstract Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs [...]

Lire la suite

Cannabinoids and Neurogenesis : The Promised Solution for Neurodegeneration ?, Andrea Valeri and Emanuela Mazzon, 2021

Cannabinoids and Neurogenesis : The Promised Solution for Neurodegeneration ? Andrea Valeri and Emanuela Mazzon Molecules, 2021, 26, 6313, 1-26. doi : 10.3390/molecules26206313   Abstract : The concept of neurons as irreplaceable cells does not hold true today. Experiments and evidence of neurogenesis, also, in the adult brain give hope that some compounds or drugs can enhance this process, helping to reverse the outcomes of diseases or traumas that once were thought to be everlasting. Cannabinoids, both from natural and artificial origins, already proved to have several beneficial effects (e.g., anti-inflammatory, anti-oxidants and analgesic action), but also capacity to increase neuronal population, by replacing the [...]

Lire la suite

Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications, Arianna Giorgetti et al., 2021

Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications Arianna Giorgetti, Jennifer P. Pascali, Paolo Fais, Guido Pelletti, Andrea Gabbin, Giorgia Franchetti, Giovanni Cecchetto  and Guido Viel Life, 2021, 11, 440, 1-17. doi : 10.3390/life11050440   Abstract : Novel psychoactive substances (NPS) represent a severe health risk for drug users. Even though the phenomenon has been growing since the early 2000s, the mechanisms of action of NPS at the receptors and beyond them are still scarcely understood. The aim of the present study was to provide a systematic review of the updated knowledge regarding the molecular [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, janvier 2022

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]

Lire la suite

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders : Molecular Mechanisms and Targets, Rosa Maria Vitale et al., 2021

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets Rosa Maria Vitale, Fabio Arturo Iannotti and Pietro Amodeo International journal of Molecular Sciences, 2021, 22, 4876, 1-20. Doi : 10.3390/ijms22094876   Abstract : Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. Albeit the molecular mechanisms responsible for the therapeutic effects of CBD have yet to be fully elucidated, many [...]

Lire la suite

Cannabidiol EPIDYOLEX 100 mg/ml, solution buvable, Première évaluation, HAS, Commisssion de la Transparence, Avis 13 mai 2020

Cannabidiol EPIDYOLEX 100 mg/ml, solution buvable Première évaluation COMMISSION DE LA TRANSPARENCE AVIS 13 MAI 2020 Haute Autorité de Santé, HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique Avis définitif    L’essentiel Avis favorable au remboursement en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut (SLG) ou au syndrome de Dravet (SD), chez les patients de 2 ans et plus.  Quel progrès ? Un progrès thérapeutique dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les patients de 2 ans et plus.  Quelle place dans la stratégie thérapeutique ? Crises d’épilepsie [...]

Lire la suite

Pharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme, Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021

Pharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme Note rédigée par l’Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021   Contexte Le Cannabidiol (CBD) est l’un des principaux phytocannabinoïdes présent dans Cannabis sativa, avec le THC. A ce jour, un seul produit contenant uniquement du CBD (nom de ce médicament Epidyolex®) est disponible sur le marché français, son Autorisation de Mise sur le Marché (AMM) lui conférant une indication médicale en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les [...]

Lire la suite

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis, Sara Arias et al., 2021

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis Sara Arias, Marta Leon, Diego Jaimes and Rosa-Helena Bustos Pharmaceuticals, 2021, 14, 78, 1-13. Doi :10.3390/ph14020078   Abstract : Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment [...]

Lire la suite